AUTL Autolus Therapeutics plc
$1.55▲ +1.31%
Healthcare
Other
Pre-market
$1.58▲ +1.94%
Oct 28, 4:20 AM ET
Volume 1.78M
Avg Volume (10D) 1.89M
Key Metrics & Fundamentals
Market Cap
$412.55M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.18 - 2.58
% vs 50 MA
-20.84%
% vs 200 MA
-6.85%
RSI-14
35.8
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.76
Free Cash Flow
-$25.98M
Gross Rev
$45.69M
Gross Profit
$25.22M
EBITDA
-$39.13M
COGS
$20.47M
Operating Exp
$69.06M
Operating Income
-$43.84M
EBIT
-$43.84M
Pretax Income
-$38.65M
Net Income
-$39.11M
EPS (Diluted)
-0.15
Price & Volume History
Loading chart…
Recent News
Autolus Therapeutics to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
GlobeNewswire · Oct 26, 2026 4:15 PM ET
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy
Zacks · Oct 5, 2026 11:00 AM ET
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
GlobeNewswire · Oct 5, 2026 8:30 AM ET
AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The Black
Insider Monkey · Sep 12, 2026 6:21 AM ET
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
GlobeNewswire · Sep 9, 2026 7:00 AM ET
Autolus Therapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 11, 2026 10:04 AM ET
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
GlobeNewswire · Aug 11, 2026 7:00 AM ET
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
GlobeNewswire · Aug 3, 2026 4:05 PM ET
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
GlobeNewswire · Aug 3, 2026 7:13 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AUTL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.